Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
4(80.0%)
N/A
1(20.0%)
5Total
Phase 1(4)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06891287Phase 1Recruiting

An Early Phase Study of RT-114 (RaniPill Containing PG-102, a GLP-1/2 Dual Agonist) in Healthy Volunteers.

Role: lead

NCT04911296Not ApplicableCompleted

Pill Swallow Study

Role: lead

NCT05890118Phase 1Completed

Study Evaluating PK of Ustekinumab Administered Orally Via RaniPill™ Capsule

Role: lead

NCT05164614Phase 1Completed

Study Evaluating PK of PTH Administered Orally Via RaniPill™ Capsule

Role: lead

NCT03798912Phase 1Completed

A First-in-Human Study of the RaniPill, an Oral Drug Delivery Platform

Role: lead

All 5 trials loaded